These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22696498)

  • 1. Naive and memory CD4⁺ T cells in HIV eradication and immunization.
    Zhang J; Poznansky M; Crumpacker C
    J Infect Dis; 2012 Aug; 206(4):617-8; author reply 618. PubMed ID: 22696498
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration.
    Méndez-Lagares G; García-Pergañeda A; del Mar del Pozo-Balado M; Genebat M; Ruiz-Mateos E; García García M; Muñoz-Fernández MÁ; Pacheco YM; Leal M
    J Antimicrob Chemother; 2012 May; 67(5):1228-37. PubMed ID: 22287235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy.
    Nicastri E; Dori L; Buonomini AR; Tommasi C; De Nardo P; Bellagamba R; Corpolongo A; Montano M; Sordillo P; Volpi A; Sarmati L; Andreoni M
    AIDS; 2012 Jul; 26(11):1451-2. PubMed ID: 22767346
    [No Abstract]   [Full Text] [Related]  

  • 4. In HIV-infected patients, some differential alterations of CD4 and CD8 T cell homeostasis may not be restored by ≥ 7 years of highly active antiretroviral therapy, in spite of good CD4 T cell repopulation.
    Bordoni V; Agrati C; Rinaldi A; Viola D; De Simone G; Gioia C; Martini F
    J Antimicrob Chemother; 2012 Jul; 67(7):1802-4. PubMed ID: 22461310
    [No Abstract]   [Full Text] [Related]  

  • 5. Naive CD4+ T lymphocytes express high levels of Bcl-2 after highly active antiretroviral therapy for HIV infection.
    Airò P; Torti C; Uccelli MC; Malacarne F; Palvarini L; Carosi G; Castelli F
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1805-7. PubMed ID: 11118066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 7. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 8. Strategies of HIV management--when to start.
    Youle M
    AIDS; 2002; 16 Suppl 4():S145-9. PubMed ID: 12699011
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
    Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
    J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.
    Li T; Wu N; Dai Y; Qiu Z; Han Y; Xie J; Zhu T; Li Y
    Clin Infect Dis; 2011 Nov; 53(9):944-51. PubMed ID: 21960716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline HIV RNA and the when to start question: time to stop asking this question?
    Mussini C
    AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
    [No Abstract]   [Full Text] [Related]  

  • 12. Less is more? STI in acute and chronic HIV-1 infection.
    Altfeld M; Walker BD
    Nat Med; 2001 Aug; 7(8):881-4. PubMed ID: 11479610
    [No Abstract]   [Full Text] [Related]  

  • 13. Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance.
    Bofill M; Martinez-Picado J; Ruiz-Hernandez R; Cabrera C; Marfil S; Erkizia I; Bellido R; Romeu J; Clotet B; Ruiz L
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):893-6. PubMed ID: 16989615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission.
    Antunes F
    Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S1-2. PubMed ID: 22156774
    [No Abstract]   [Full Text] [Related]  

  • 18. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
    Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
    Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
    J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.